3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
58
Neoplasms
51
Lung Neoplasms
33
Colorectal Neoplasms
28
Carcinoma, Non-Small-Cell Lung
25
Prostatic Neoplasms
22
Melanoma
19
Pancreatic Neoplasms
17
Ovarian Neoplasms
16
Uterine Cervical Neoplasms
14
Sarcoma
12
Multiple Myeloma
12
Lymphoma
11
Glioma
11
Glioblastoma
11
Neoplasm Metastasis
10
Leukemia, Myeloid, Acute
10
Colonic Neoplasms
10
Neoplastic Cells, Circulating
9
Hematologic Neoplasms
9
Lymphoma, Follicular
8
Head and Neck Neoplasms
8
Carcinoma, Hepatocellular
8
Leukemia
7
Endometrial Neoplasms
7
Brain Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Papillomavirus Infections
6
Myelodysplastic Syndromes
6
Disease
6
Interventions
pembrolizumab
7
lenvatinib
3
apatinib
3
Magnetic Resonance Spectroscopy
3
Imatinib Mesylate
3
Carboplatin
3
gallium 68 PSMA-11
2
Specimen Handling
2
Protons
2
Nivolumab
2
Epirubicin
2
Cisplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tislelizumab
1
regorafenib
1
enfortumab vedotin
1
cabozantinib
1
avelumab
1
anlotinib
1
amivantamab
1
abemaciclib
1
Tretinoin
1
Trastuzumab
1
Tablets
1
Sunitinib
1
Standard of Care
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Adenoid Cystic
×
Blood Specimen Collection
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled